Primary colorectal cancers and their subsequent hepatic metastases are genetically different: Implications for selection of patients for targeted treatment

Clinical Cancer Research

Volumn 18, Issue 3, 2012, Pages 688-699

  Vermaat, Joost S ^a   Nijman, Isaac J ^b   Koudijs, Marco J ^a   Gerritse, Frank L ^a   Scherer, Stefan J ^c   Mokry, Michal ^b   Roessingh, Wijnand M ^a   Lansu, Nico ^b   De Bruijn, Ewart ^b   Van Hillegersberg, Richard ^a   Van Diest, Paul J ^a   Cuppen, Edwin ^a,b   Voest, Emile E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b HUBRECHT INSTITUTE   (Netherlands)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; PARAFFIN;

ADULT; ARTICLE; BRAF GENE; CANCER GENETICS; CANCER SURGERY; CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DNA ISOLATION; DNA SEQUENCE; EGFR GENE; EXON; FEMALE; FLT1 GENE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME; HUMAN; HUMAN TISSUE; KDR GENE; KRAS GENE; LIVER METASTASIS; MALE; MOLECULARLY TARGETED THERAPY; MTOR GENE; PATIENT SELECTION; PERSONALIZED MEDICINE; PI3K GENE; PI3KCA GENE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN FUNCTION; PTEN GENE; TREATMENT RESPONSE; VEGF GENE;

ADENOCARCINOMA; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; POLYMERASE CHAIN REACTION;

EID: 84856536814     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1965     Document Type: Article

References (56)

1. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CEJr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84. (Pubitemid 41464706)
2. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009;27: 2622-9.
3. Di NF, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26: 5705-12.
4. Lievre A, Bachet JB, Le CD, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
5. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72.
6. Garm Spindler KL, Pallisgaard N, Rasmussen AA, Lindebjerg J, Andersen RF, Cruger D, et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 2009;20:879-84.
7. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254-61.
8. Hawkes E, Cunningham D. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies. J Clin Oncol 2010;28:e529-31.
9. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-300. (Pubitemid 44706932)
10. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res 2009;154:277-87.
11. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature 2008;452:553-63. (Pubitemid 351483369)
12. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99. (Pubitemid 39070849)
13. SjoblomT, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74. (Pubitemid 44571966)
14. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009;9:274-84.
15. Nijman IJ, Mokry M, van BR, Toonen P, de Bruijn E, Cuppen E. Mutation discovery by targeted genomic enrichment of multiplexed barcoded samples. Nat Methods 2010;7:913-5.
16. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298: 1912-34. (Pubitemid 35425239)
17. Sjoblom T. Systematic analyses of the cancer genome: lessons learned from sequencing most of the annotated human protein-coding genes. Curr Opin Oncol 2008;20:66-71. (Pubitemid 350190983)
18. Mokry M, Feitsma H, Nijman IJ, de Bruijn E, van der Zaag PJ, Guryev V, et al. Accurate SNP and mutation detection by targeted custom microarray-based genomic enrichment of short-fragment sequencing libraries. Nucleic Acids Res 2010;38:e116.
19. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010;26:589-95.
20. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
21. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13. (Pubitemid 350134889)
22. Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, Mardis ER, et al. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics 2009;25:2283-5.
23. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297-303.
24. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9.
25. Chen J, Huang XF, Katsifis A. Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. J Cell Biochem 2010;111:1082-6.
26. Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res 2010;16:3811-8.
27. Knijn N, Mekenkamp LJ, Klomp M, Vink-Borger ME, Tol J, Teerenstra S, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011;104:1020-6.
28. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009;27:5924-30.
29. Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, et al. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol 2011;68: 1045-55.
30. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009;27:5931-7.
31. Ocana A, Pandiella A. Personalized therapies in the cancer "omics" era. Mol Cancer 2010;9:202.
32. Mariani P, Lae M, Degeorges A, Cacheux W, Lappartient E, Margogne A, et al. Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. Anticancer Res 2010;30: 4229-35.
33. Bell DW. Our changing view of the genomic landscape of cancer. J Pathol 2010;220:231-43.
34. Goasguen N, de Chaisemartin C, Brouquet A, Julie C, Prevost GP, Laurent-Puig P, et al. Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents. Int J Cancer 2010;127: 1028-37.
35. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010;1805:105-17.
36. Salk JJ, Fox EJ, Loeb LA. Mutational heterogeneity in human cancers: origin and consequences. Annu Rev Pathol 2010;5:51-75.
37. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008;105:4283-8. (Pubitemid 351754372)
38. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-13.
39. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010;464:999-1005.
40. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010;467:1109-13.
41. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-7.
42. Goranova TE, Ohue M, Shimoharu Y, Kato K. Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. Clin Exp Metastasis 2011;8:427-35
43. Velculescu VE. Defining the blueprint of the cancer genome. Carcinogenesis 2008;29:1087-91. (Pubitemid 351958685)
44. Schweiger MR, Kerick M, Timmermann B, Albrecht MW, et al. Genome-wide massively parallel sequencing of FFPE tumor tissues for copy-number- and mutation-analysis. PLoS One 2009;4:e5548.
45. Hawkins RD, Hon GC, Ren B. Next-generation genomics: an integrative approach. Nat Rev Genet 2010;11:476-86.
46. Mamanova L, Coffey AJ, Scott CE, Kozarewa I, Turner EH, Kumar A, et al. Target-enrichment strategies for next-generation sequencing. Nat Methods 2010;7:111-8.
47. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010;11:31-46.
48. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008;26:1135-45.
49. Swanton C, Caldas C. Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer 2009;100:1517-22.
50. Baudot A, de la Torre V, Valencia A. Mutated genes, pathways and processes in tumours. EMBO Rep 2010;11:805-10.
51. Chittenden TW, Howe EA, Culhane AC, Sultana R, Taylor JM, Holmes C, et al. Functional classification analysis of somatically mutated genes in human breast and colorectal cancers. Genomics 2008;91:508-11.
52. Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A 2006;103:5923-8.
53. Ding L, Wendl MC, Koboldt DC, Mardis ER. Analysis of next-generation genomic data in cancer: accomplishments and challenges. Hum Mol Genet 2010;19:R188-96.
54. Appelbaum L, Kane RA, Kruskal JB, Romero J, Sosna J. Focal hepatic lesions: US-guided biopsy-lessons from review of cytologic and pathologic examination results. Radiology 2009;250:453-8.
55. Terjung B, Lemnitzer I, Dumoulin FL, Effenberger W, Brackmann HH, Sauerbruch T, et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003;673: 138-45. (Pubitemid 36829079)
56. Thanos L, Zormpala A, Papaioannou G, Malagari K, Brountzos E, Kelekis D. Safety and efficacy of percutaneous CT-guided liver biopsy using an 18-gauge automated needle. Eur J Intern Med 2005;16: 571-4. (Pubitemid 41728211)